Winatin

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Winatin

Quick Facts

Property Description
Active ingredient Loratadine
Form Oral (Tablets, Syrup, Oral Solution)
Pharmacological class H₁-Antihistamine
General purpose Relief from allergic response symptoms
Origin Synthetic tricyclic compound

What Type of Medicine is Winatin?

Winatin is a medication centered on the active ingredient Loratadine, which belongs to the pharmacological class of second-generation tricyclic H₁-antihistamines. This classification defines the drug’s primary function as an antiallergic agent, designed to manage the physiological response to histamine release. Loratadine is entirely synthetic in origin, unlike some agents derived from natural sources. As a modern entity in its class, its profile is clinically recognized for selectively managing the effects of histamine. The medication is structured as a single-active-ingredient product, which directs its therapeutic effects entirely to the action of the Loratadine molecule, minimizing complexity in its pharmacological profile.


Composition, Forms, and General Purpose

The composition of Winatin consists of the Loratadine compound alongside various inert pharmaceutical excipients needed to create stable oral dosage forms, such as traditional tablets and oral solution or syrup. The availability of both solid and liquid forms makes it a versatile choice for a broad patient group, accommodating adults and pediatric populations who may require liquid preparations. The drug's general therapeutic purpose is rooted in its highly selective mechanism of histamine blocking, which provides relief from the symptoms associated with H₁-mediated allergic conditions; second-generation antihistamines, including Loratadine, are effective in controlling these allergy symptoms. As a key attribute of its class, the compound exhibits minimal blood-brain barrier penetration, a characteristic that reinforces its profile as a non-sedating option for daily use.

Regulatory References

  1. MedlinePlus: Loratadine Information

What side effects are possible with Winatin?

The possible side effects and safety characteristics of Winatin (Loratadine) are categorized and documented in official regulatory sources, such as the EMA and FDA. These documents structure the medicine's safety profile by frequency, system involvement, and special population considerations.

Adverse Reaction Categories

Classification Adverse Reactions (by System-Organ Class)
Common Nervous system (Headache, Somnolence/Drowsiness), Investigations (Increased Appetite), Psychiatric (Insomnia). For children 2–12 years, Nervousness and Fatigue are also listed as common.
Very Rare Immune System (Hypersensitivity reactions including Anaphylaxis and Angioedema), Nervous System (Dizziness, Convulsion), Cardiac (Tachycardia, Palpitation), Gastrointestinal (Nausea, Dry mouth), Hepatobiliary (Abnormal Hepatic Function), Skin (Rash, Alopecia).
Not Known Weight increased.

Serious Adverse Reactions

The label documents specific very rare events considered serious, which include severe Hypersensitivity Reactions (such as anaphylaxis), Convulsion (seizures), and Abnormal Hepatic Function (liver problems).

Safety Considerations and Restrictions

Official labels address specific populations and contexts:

  • Severe Hepatic Impairment: Caution is required, as the clearance of Loratadine may be reduced. A lower initial dose may be necessary.
  • Pregnancy and Breast-feeding: Use during pregnancy is generally advised against as a precautionary measure. Use is not recommended while breast-feeding, as the drug is excreted in breast milk.
  • Allergy Testing: The medicine must be discontinued at least 48 hours prior to any skin allergy testing, as antihistamines can interfere with the test results.

Overdose and Emergency Response

The official regulatory profile for Winatin (Loratadine) overdose emphasizes immediate medical intervention when exposure to excessive amounts is suspected. Documented manifestations reported in cases of overdose include central nervous system effects such as somnolence (drowsiness) and headache. Cardiovascular findings, specifically tachycardia (fast or pounding heartbeat), have also been recorded in overdose reports. Due to the potential for serious physiological effects, including an increased occurrence of anticholinergic symptoms, the FDA and other regulatory authorities mandate that urgent medical attention must be sought immediately. In case of suspected overdose, individuals must get medical help or contact a Poison Control Center right away.

Management of Loratadine overdose is strictly symptomatic and supportive, based on the official procedural instructions for healthcare providers. Specific intervention measures that may be considered include the administration of activated charcoal as a slurry with water or gastric lavage. No specific antidote for Loratadine is known, and regulatory documentation confirms that the substance is not eliminated by haemodialysis. Following the initiation of emergency procedures, medical monitoring of the patient must be continued to ensure stability and observation of clinical status.

Therapeutic Uses of Winatin

Quick Facts: Winatin

Condition
Seasonal allergic rhinitis (hay fever)
Chronic hives (urticaria)
Symptoms associated with outdoor and indoor allergies

Winatin is an approved medication intended for use in managing specific allergic conditions. Its primary application is for the symptomatic management of seasonal allergic rhinitis, commonly known as hay fever. This use helps to address associated discomforts, which may include sneezing, runny nose (rhinorrhea), and irritation of the nasal passages or throat.

In addition to seasonal allergies, Winatin is utilized in the care of individuals experiencing chronic idiopathic urticaria (hives) to help mitigate symptoms such as itching and the appearance of raised welts on the skin. The medication is part of a therapeutic regimen that aims to provide general relief from the common signs and manifestations of allergic responses, supporting comfort for the affected individual. It is generally regarded as an option for alleviating symptoms related to upper respiratory allergies.

This medication is solely indicated for these therapeutic domains and is not a suitable option for the emergency management of severe allergic reactions (e.g., anaphylaxis).

Eligibility and Restrictions for Use

Eligibility Map: Official Regulatory Information

Winatin is authorized for use in specific populations as defined by regulatory bodies, with clear exclusions and restrictions based on age, physiological status, and underlying conditions.

Populations for Whom Use is Contraindicated

Winatin is formally contraindicated in two primary groups. The first is patients with a known hypersensitivity to the active substance, Loratadine, or to any of the product’s excipients. The second exclusion is for children under 2 years of age, as the safety and efficacy of the medicine have not been established in this young population.

Age-Group Eligibility

The medicine is authorized for standard use in adults and adolescents (12 years and older) and in children 6 years and older. Children between 2 and 6 years of age are approved only for use with the oral solution formulation.

Restricted and Conditional Use

Severe organ impairment requires a modification of standard use. Patients with severe hepatic impairment or severe renal insufficiency must use the medicine under a restricted dosing schedule to manage drug clearance. Furthermore, use is not recommended during both pregnancy and breastfeeding as a precautionary measure. Use must also be discontinued 48 hours before planned allergy skin testing.

What should I know about interactions with other medicines?

Winatin's official interaction profile is governed primarily by documented pharmacokinetic patterns related to its metabolism. Co-administration with certain medicinal products is documented to cause a substantial interaction resulting in significantly elevated systemic exposure. Inhibitors of the CYP3A4 and CYP2D6 metabolic enzymes, specifically Ketoconazole, Erythromycin, and Cimetidine, are known to substantially increase the plasma concentrations (AUC) of both Loratadine and its active metabolite, Desloratadine, a key regulatory finding.


Documented Exposure and Pharmacodynamic Effects

Classification Interacting Entity Official Regulatory Statement
Metabolic Increase Ketoconazole, Erythromycin, Cimetidine Substantially increase plasma AUC of Loratadine and its metabolite.
Pharmacodynamic CNS Depressants Potential for additive sedation when co-administered.
Substance Effect Alcohol Documented as having no potentiating effect on psychomotor performance.

Timing and Population Notes

For diagnostic procedures, the medication must be stopped at least 48 hours prior to histamine skin testing to prevent interference with the test results. Ingestion with food increases the systemic bioavailability of the drug by approximately 40-48%. Regulatory documentation notes that patients with severe hepatic impairment or decreased renal function (GFR le 30 mL/min) are at greater risk for drug and metabolite accumulation due to reduced clearance, a factor influencing interaction severity.

Mechanism of Action

How Winatin Works

Winatin's mechanism is defined by its action as a pro-drug, rapidly converting into the active metabolite, Desloratadine. This metabolite operates as an Inverse Agonist on the Peripheral Histamine H1 Receptor ( H1 R), stabilizing the receptor in an inactive conformation. This molecular change functionally suppresses the H1 R and blocks the associated G q/11 signaling cascade.

This interaction results in the suppression of H1-mediated signaling, which prevents the activation of downstream cascades responsible for increasing vascular permeability and stimulating sensory nerves. The mechanism demonstrates strong peripheral selectivity due to the molecule's inability to significantly penetrate the Blood-Brain Barrier (BBB). This limits H1 R occupancy in the Central Nervous System, ensuring the mechanism does not significantly modulate the central pathways that regulate alertness and sleep cycles.

The mechanism's strict H1 specificity constrains its influence on other systems, such as alpha-adrenergic signaling pathways, thereby limiting the scope of its effect on certain vascular-driven physiological changes.

Dosage and Administration Information

How to Use Winatin: Administration Guidelines

This section summarizes the instructions for administering Winatin. This information is descriptive and not intended as medical advice.


Administration Scope

Instruction Entity Administration Guideline
Route of administration Oral (tablet, disintegrating tablet, syrup) OR Subcutaneous injection (autoinjector), depending on the specific labeled product form.
Standard Dosing Schedule Oral: 10 mg once daily. OR Injection: 45 mg once monthly.
Timing in relation to meals May be taken with or without food.
Preparation requirements Injection Form: Allow autoinjector to warm for 30 minutes to room temperature prior to use. Oral Liquid: Measure the dose using a calibrated device.
Age-group rules Dosing adjustments are required for certain pediatric age groups and are specified for individuals with severe hepatic or renal impairment.
Missed-dose rule For the monthly injection, administer the missed dose as soon as possible and resume the monthly cycle from the new date of injection.

Procedural Structure

The protocol for Winatin use is dependent on the chosen dosage form. For oral administration, the dose is limited to once daily. Users of the orally disintegrating tablet must allow the tablet to dissolve on the tongue before swallowing. For the subcutaneous injection, the medicine must be prepared by allowing it to warm and is then administered into the abdomen or upper thigh.

Administration involves adherence to the dose and frequency, whether the regimen is daily or monthly. The full use protocol outlines specific procedural steps, such as inspecting the liquid for the injectable form, and defines dose reductions for patients with severe organ impairment, ensuring the correct use pattern is followed.

Recent Clinical Evidence

Research evidence / Overview of Studies for Winatin (Loratadine)


Evidence for Use in Seasonal and Perennial Allergic Rhinitis

Research was studied for use in allergic rhinitis (hay fever and year-round allergies), a condition marked by episodic manifestations like sneezing, runny nose, and itching. The evidence primarily consists of short-term, randomized, placebo-controlled clinical trials (RCTs) used in research exploring how symptoms change over time in adults and children aged six years and older. Outcomes research examined included standardized measures like the Total Symptom Score, which combines measures that include nasal and ocular symptoms, outcomes related to physical discomfort.

Findings describe patterns observed in the studies where symptom scores were measured and compared against those who received an inactive substance (placebo). The evidence base for this indication, consisting of multiple trials, is cited in regulatory summaries.


Research Evidence for Chronic Hives (Chronic Idiopathic Urticaria)

Winatin was studied for its use in Chronic Idiopathic Urticaria (CIU), a condition characterized by fluctuating or episodic manifestations of wheals (hives) and persistent itching. The research base involves controlled clinical trials conducted in adults and adolescents. These studies explored how the medication affects key patient-reported outcomes describing perceived discomfort, such as the severity of itching (pruritus) and the number and size of visible skin lesions.

Controlled trials findings describe patterns observed in the studies where participants reported changes in their urticaria-related symptoms compared to the control groups. Clinical evidence contributes to the broader evidence landscape for exploring changes in outcomes related to physical discomfort associated with CIU.


Research in Pediatric Populations

Research was evaluated in specific pediatric age groups, including children aged two to under six years and those six years and older. These studies research examined the drug's absorption and clearance profiles, and efficacy studies were observed in pediatric cohorts. Reports on high-level adverse events during these trials described frequencies and types of events that were generally comparable between the study group and the placebo group.


The Scientific Consensus and Remaining Gaps

The evidence base for Winatin is substantive and foundational for its approved indications. This foundation is built on multiple short-term, placebo-controlled RCTs that studies explored the effect on patient-reported outcomes describing perceived discomfort. However, long-term effects are not fully established based on dedicated, multi-year trials. There is limited information for long-term outcomes, and safety and effectiveness have not been established in children under two years of age. Research is ongoing to further examine its comparative performance within the entire class of second-generation antihistamines.

Key Studies & References Loratadine Drug Information

Frequently Asked Questions (FAQ)

Common questions about Winatin (FAQ)


Q: Are there any common over-the-counter medicines that interact with Winatin?

Official documents list known interactions with specific medicinal products like Cimetidine and Erythromycin, as well as the drug class of CNS depressants. Official guidance states that patients should inform a healthcare professional about all products being taken, including over-the-counter medicines, herbal remedies, vitamins, and supplements.


Q: Why do some people say they take Winatin in the morning versus the evening?

According to the official product information, Winatin is taken just once daily. The drug’s active component has a long duration of action, typically lasting up to 24 hours. This means that taking it in the morning or the evening does not usually change its effectiveness in providing symptom relief throughout the day.


Q: Are there warnings about Winatin for people with heart conditions?

Official regulatory documents list heart-related issues, such as Tachycardia (a rapid heart rate) and Palpitation, among the very rare adverse reactions. Regulatory information indicates that individuals with pre-existing heart conditions are generally advised to discuss their full medical history with a healthcare professional.


Q: Can women who are planning pregnancy use Winatin?

Use of Winatin is generally advised against as a precautionary measure during established pregnancy. Individuals who are planning to become pregnant or who are pregnant while taking this medicine should review the relevant regulatory guidance with a healthcare professional for specific information regarding their use.


Q: What is the difference between Winatin and its alternatives?

Winatin is a second-generation H₁-antihistamine. Its mechanism of action features strong peripheral selectivity, which means it has minimal ability to enter the central nervous system. This characteristic, which is cited in the regulatory documents, is the basis for its non-sedating profile when compared to some other types of antihistamines.


Q: What does the official patient leaflet say about driving while on Winatin?

Official product information cautions that while the medicine is generally non-sedating, some users may still experience drowsiness or somnolence. Official regulatory information typically states that patients should use caution and determine their individual response before operating complex machinery or driving.


Q: What is the difference between different dosages of Winatin?

The official product labeling authorizes two standard administration schedules based on the product form. This includes a once-daily dose for oral forms and a once-monthly dose for the subcutaneous injection form. Both schedules are dependent on the specific formulation chosen for use.


Q: What are the signs of a rare but serious adverse event with Winatin?

Regulatory documents indicate that very rare, serious adverse events can occur, including Convulsion (seizures) and signs of Abnormal Hepatic Function (liver problems). Hypersensitivity reactions, such as anaphylaxis and angioedema, have also been reported. Immediate emergency medical assistance is typically sought if a severe allergic reaction occurs.


Q: What are the restrictions on using Winatin before surgery?

The medicine is required to be discontinued at least 48 hours before any planned histamine skin testing to prevent interference with the test results. Official labeling generally states that patients should inform all healthcare providers, including surgeons or dentists, that they are taking Winatin before undergoing any type of medical or surgical procedure.


Q: What is the purpose of the different inactive ingredients in Winatin tablets?

The official composition of Winatin includes the active ingredient, Loratadine, and various inert pharmaceutical excipients (inactive ingredients). These inactive components are included to ensure the drug is stable, has the proper volume, and can be accurately measured and administered in its final oral dosage form.


Q: How long does it usually take to notice an effect from Winatin?

Studies cited in the regulatory context indicate the onset of action for symptom relief can be observed relatively quickly after administration. For the oral tablet form, symptom relief may begin as early as 75 minutes following the initial dose.


Q: Does Winatin stay in your system for a long time?

According to official pharmacokinetic information, the drug and its main active metabolite remain in the body for an extended period. The long elimination half-life of the active metabolite, which can be up to 28 hours, supports the recommended once-daily administration schedule for 24-hour symptom relief.


Q: Can Winatin be used by older adults?

Official regulatory information does not require specific dosing adjustments for the general older adult population. However, regulatory information typically includes a cautionary note for patients with severe liver or kidney impairment, as these conditions may affect how the drug is cleared from the body.


Q: Is Winatin a controlled substance or addictive?

Winatin (Loratadine) is not scheduled or classified as a controlled substance under federal regulations. The medicine is not associated with the potential for abuse or physical dependence.


Q: Is there a generic version of Winatin available?

The active ingredient in Winatin, Loratadine, is widely available as an over-the-counter medicine. Regulatory documents confirm that it has received approval for generic status.


Q: Does Winatin have a 'Black Box Warning' from the FDA?

The official labeling for single-ingredient Winatin (Loratadine) does not currently contain an FDA Boxed Warning. This specific type of warning, sometimes called a Black Box Warning, is reserved for communicating known serious hazards in the prescribing information.


Q: How is Winatin absorbed by the body?

Following oral administration, Winatin (Loratadine) is rapidly absorbed and functions as a pro-drug, which means the body quickly converts it into its primary active metabolite, Desloratadine. Official information notes that ingestion with food can increase the overall amount of the drug absorbed into the system.


Q: Can Winatin be taken with vitamins or supplements?

Official guidance states that patients should inform a healthcare professional about all products they are taking. This includes all vitamins, mineral supplements, and herbal remedies, due to the potential for undocumented interactions with the medicine.


Q: Does Winatin interact with grapefruit?

Regulatory-cited sources have not documented a significant interaction between single-ingredient Winatin and grapefruit juice. While the official label notes interactions with certain metabolic enzyme inhibitors, the need to avoid grapefruit juice is not specified.


Q: What regulatory bodies have approved Winatin?

The authoritative regulatory information for this medicine is based on documents from global regulatory agencies. These agencies include the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).


Q: Is Winatin used in combination with other treatments?

Official regulatory information confirms that Winatin (Loratadine) is used as both a single-ingredient product and in fixed-dose combination with other active components. A common regulated combination includes the nasal decongestant Pseudoephedrine.


Q: What should a patient do if they accidentally take too much Winatin?

The official patient information states that in the event of an accidental overdose, immediate emergency medical help is typically sought. Official guidance indicates that a Poison Control Center should be contacted right away for specific guidance.


How should Winatin be stored and disposed of?

Storing and Disposing of Winatin (Loratadine)

Winatin must be stored and handled according to the following official requirements to maintain product stability and safety.

Storage Conditions

Requirement Specifics
Temperature Store at controlled room temperature, between 20 C and 25 C (68 F to 77 F).
Protection Protect from excessive moisture; the oral solution must be protected from freezing.
Container Do not use if the tamper-evident seal is missing or broken.
Child Safety The medicine must be kept out of the reach of children.

Disposal

Disposal must adhere to federal guidelines. Do not flush the medication down a sink or toilet unless explicitly directed by the label. If no drug take-back program is available, unused product should be mixed with an undesirable substance, placed in a sealed container, and discarded in the household trash. Identifying information must be removed from the container before disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Winatin found in:

A-Z Index: